| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-09-23 | dalantercept | ovarian cancer |
Acceleron Pharma (USA - MA) | Cancer - Oncology | |
| 2014-09-23 | BOW015 (infliximab - biosimilar version of Remicade®) | rheumatoid arthritis |
3 | Epirus Switzerland (Switzerland) EPIRUS Biopharmaceuticals (USA - MA) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2014-09-22 | LMTX™ (leuco-methylthioninium) | mild to moderate Alzheimer's Disease |
3 | TauRx Therapeutics (Singapore - UK) | Neurodegenerative diseases |
| 2014-09-22 | anti-aging compounds | preclinical | Sirona Biochem (Canada - France) Biogalenys (France) | ||
| 2014-09-22 | MPDL3280A (atezolizumab) and Avastin® (bevacizumab) | metastatic renal cell carcinoma | 1b | Roche (Switzerland) | Cancer - Oncology |
| 2014-09-22 | PRM-151 (recombinant human pentraxin-2) | idiopathic pulmonary fibrosis |
1b | Promedior (USA - MA) | Lung diseases - Respiratory diseases - Rare diseases |
| 2014-09-19 | asfotase alfa (alkaline phosphatase) | hypophosphatasia | 2 | Alexion Pharmaceuticals (USA - CT) | Bone diseases - Genetic diseases - Metabolic diseases |
| 2014-09-19 | Xultophy®/IDegLira (combination of insulin degludec (Tresiba®) and liraglutide (Victoza®)) | type 2 diabetes |
3a | Novo Nordisk (Denmark) | Metabolic diseases |
| 2014-09-19 | LBH589 (panobinostat) | multiple myeloma |
3 | Novartis (Switzerland) | Cancer - Oncology |
| 2014-09-19 | Lyxumia® (lixisenatide) | type 2 diabetes |
Sanofi (France) Zealand Pharma (Denmark) | Metabolic diseases | |
| 2014-09-19 | LixiLan® (single injection Lyxumia®(lixisenatide) /Lantus® (basal insuline) combination product | type 2 diabetes | 2b | Sanofi (France) Zealand Pharma (Denmark) | Metabolic diseases |
| 2014-09-18 | ARGX-110 | CD70-positive hematological and virally-induced solid tumors |
1b | Argen-X (The Netherlands-Belgium) | Cancer - Oncology |
| 2014-09-18 | DiaPep277® | type 1 diabetes |
3 | Andromeda Biotech (Israel) Evotec (Germany) | Metabolic diseases |
| 2014-09-17 | GRC 17536 | diabetic neuropathy |
2a | Glenmark Pharmaceuticals (India) | CNS diseases - Metabolic diseases |
| 2014-09-17 | OpRegen® | dry form age-related macular degeneration (dry-AMD) |
preclinical | BioTime (USA - CA) HBL Hadasit Bio-Holdings (Israel) Cell Cure Neurosciences (Israel) | Ophtalmological diseases |
| 2014-09-17 | Halaven® (eribulin) | metastatic breast cancer | Eisai (Japan) | Cancer - Oncology | |
| 2014-09-17 | lenvatinib | radioiodine-refractory differentiated thyroid cancer |
Eisai (Japan) | Cancer - Oncology | |
| 2014-09-17 | MOB-015 | onychomycosis |
2 | Moberg Derma (Sweden) | Infectious diseases |
| 2014-09-17 | simtuzumab | previously untreated advanced pancreatic cancer |
2 | Gilead Sciences (USA - CA) | Cancer - Oncology |
| 2014-09-16 | Tresiba® (insulin degludec) | type 1 diabetes |
Novo Nordisk (Denmark) | Metabolic diseases |
